Dicloxacillin

Summary

Dicloxacillin (CHEMBL893) is an approved small-molecule antibacterial drug (ATC J01CF01); indicated across 4 conditions including bacterial infectious disease and gram-positive bacterial infections.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CF01
• Indications: 4 conditions
• Clinical trials: 7
• Chemistry: 470.3 Da · C19H17Cl2N3O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL893
Name	Dicloxacillin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	18381
ChEBI	CHEBI:4511
ATC	J01CF01
Molecular formula	C19H17Cl2N3O5S
Molecular weight	470.3
InChIKey	YFAGHNZHGGCZAX-JKIFEVAISA-N

SMILES: CC1=C(C(=NO1)C2=C(C=CC=C2Cl)Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O

IUPAC name: (2S,5R,6R)-6-[[3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: BRL-1702, Dicloxacilina, Dicloxacillin, Dicloxacilline, R-13423, dicloxacillin, DICLOXACILLIN, SID124893598, DICLOXACILLINE

Parent form; salt/anhydrous children: CHEMBL26570, CHEMBL1200701

Patent coverage: 6,475 distinct patent families (26,391 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Organic anion transporter 3, Bile salt export pump.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
bacterial infectious disease with sepsis	3	MONDO:0005229	EFO:0003033
gram-positive bacterial infections	3	MONDO:0021679	MONDO:0021679
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE4	3
PHASE1	2
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05398679	PHASE4	RECRUITING	Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis
NCT05156437	PHASE4	TERMINATED	Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL)
NCT05578482	PHASE4	UNKNOWN	Staphylococcus Aureus and The Skin Microbiome During Flare And Resolution Of Atopic Dermatitis
NCT00037050	PHASE3	COMPLETED	Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
NCT02983890	PHASE1	COMPLETED	Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.
NCT05073627	PHASE1	COMPLETED	The Effect of Dicloxacillin on Oral Absorption of Drugs
NCT00162474	Not specified	RECRUITING	Determinants of Warfarin Metabolism

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 2 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).